Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 674 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Halozyme Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 357 | 4 | 423 | +70 |
| Shares | 131.7M | 393.0K | 129.2M | −2.09M (−1.6%) |
| Value | $5.21B | $15.6M | $7.35B | +$2.16B (+41.5%) |
4 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (90)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (20)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Arrowstreet Capital, Limited Partnership | 271,615 | $10.7M |
| UBS Oconnor LLC | 83,937 | $3.32M |
| LMR Partners LLP | 74,500 | $2.95M |
| APG Asset Management N.V. | 44,300 | $1.79M |
| Natixis | 37,600 | $1.49M |
| Kiwi Wealth Investments Limited Partnership | 18,707 | $823.1K |
| Boulder Hill Capital Management LP | 19,100 | $755.0K |
| Financial Advocates Investment Management | 6,421 | $541.0K |
| KBC Group NV | 13,061 | $516.0K |
| AlphaCrest Capital Management LLC | 10,972 | $434.0K |
| Illinois Municipal Retirement Fund | 9,969 | $394.0K |
| Cim Investment Mangement Inc | 7,769 | $307.0K |
| PDT Partners, LLC | 6,000 | $237.0K |
| Simplex Trading, LLC | 3,831 | $151.0K |
| Almanack Investment Partners, LLC. | 1,382 | $55.0K |
| Elequin Capital LP | 468 | $19.0K |
| Meeder Asset Management Inc | 170 | $7.00K |
| Bogart Wealth, LLC | 50 | $2.00K |
| Raffa Wealth Management, LLC | 33 | $1.30K |
| Leonteq Securities AG | 6 | $237 |
Not filed for Q4 2022 yet (4)
Institutions that held Halozyme Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Covington Capital Management | 247,500 | $9.79M |
| Eaton Vance Management | 139,396 | $5.51M |
| Corient Capital Partners, LLC | 4,627 | $204.0K |
| Wipfli Financial Advisors LLC, | 1,519 | $60.0K |